Vinod Chainani, MD
Interventional Cardiology · Miami, FLNPI 1174830178
Payments from drug & device makers
What this record shows
This record is dominated by other: $41,333 of the $68,526 with a category attached, or 60.3%. Angiodynamics, Inc. accounts for 62.2% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2024 at $23,129 and has fallen 86.2% since, to $3,194 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $292.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$43K
- Surmodics, Inc.$10K
- Cook Medical LLC$4K
- Medtronic$2K
- Philips North America LLC$1K
- Bard Peripheral Vascular, Inc.$943
- plus $7K from 33 others
Across 1 payment — averaging $27,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$27K
What the payments were for
- Consulting fees$7,22511%
- Grants$4,4887%
- Travel & lodging$2,4734%
- Food & beverage$12,34918%
- Education$6581%
- Other$41,33360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 14 | $42,634 |
| Surmodics, Inc. | 22 | $9,956 |
| Cook Medical LLC | 1 | $4,488 |
| Medtronic(2 entities) | 40 | $2,354 |
| Philips North America LLC | 14 | $1,162 |
| Bard Peripheral Vascular, Inc. | 11 | $943 |
| Inari Medical, Inc. | 3 | $756 |
| Abiomed | 15 | $571 |
| AstraZeneca | 12 | $501 |
| Shockwave Medical, Inc | 5 | $488 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $457 |
| Johnson & Johnson | 12 | $390 |
| Boston Scientific | 7 | $346 |
| Abbott | 6 | $338 |
| Asahi Intecc USA, Inc. | 7 | $317 |
| ZOLL Circulation Inc | 4 | $289 |
| Pfizer | 5 | $279 |
| BD | 4 | $211 |
| Stryker | 3 | $195 |
| Cardiovascular Systems Inc. | 2 | $183 |
| Silk Road Medical, Inc. | 1 | $180 |
| Novartis | 3 | $172 |
| Veryan Medical Incorporated | 2 | $162 |
| Heartflow, Inc. | 1 | $149 |
| Biotronik Inc. | 2 | $145 |
| Novo Nordisk | 2 | $142 |
| Penumbra, Inc. | 2 | $127 |
| Lantheus Medical Imaging, Inc. | 1 | $124 |
| Nevro Corp. | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Cordis US CORP. | 3 | $62 |
| Akcea Therapeutics, Inc. | 3 | $60 |
| Cardiva Medical, Inc. | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Neural Analytics, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$41,939
- Pounce Venous Thrombectomy System$9,557
- Pounce Thrombectomy$1,647
- Pounce Thrombectomy System$1,647
- Pounce LP Thrombectomy$1,414
- FlowTriever$756
- ClotTriever$756
- VenaCure 1470 Pro$513
- Turbo Elite$443
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$420
- ClosureFast$319
- SYMPLICITY G3$287
- Impella$257
- Resolute$254
- Sublime 014 Rx PTA Balloon Dilatation Catheter$233
- Sublime Microcatheter, 018, 200cm, Straight$233
- ONYX FRONTIER$205
- ENROUTE Transcarotid Neuroprotection System$180
- ENROUTE Transcarotid Stent$180
- AZURE XT DR MRI SURESCAN$180
How this compares
$68,526 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 70 | $86,969 |
| EliquisApixaban | 77 | $85,420 |
| XareltoRivaroxaban | 88 | $72,518 |
| FarxigaDapagliflozin Propanediol | 40 | $44,264 |
| BrilintaTicagrelor | 40 | $31,165 |
| MounjaroTirzepatide | 13 | $14,081 |
| Cilostazol | 139 | $2,860 |
| Ranolazine ErRanolazine | 23 | $1,985 |
| Atorvastatin Calcium | 241 | $1,955 |
| ClopidogrelClopidogrel Bisulfate | 172 | $1,622 |
| Doxazosin Mesylate | 84 | $1,135 |
| Nifedipine ErNifedipine | 51 | $743 |
| Metoprolol Succinate | 119 | $712 |
| Bumetanide | 36 | $584 |
| Rosuvastatin Calcium | 51 | $490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $172 | $86,96970 claims |
| PfizerEliquis | $279 | $85,42077 claims |
| AstraZenecaFarxiga, Brilinta | $501 | $75,43080 claims |
| Johnson & JohnsonXarelto | $390 | $72,51888 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Eduardo de MarchenaMiami$498K
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Nish PatelMiami$149K
- Pedro Martinez-ClarkMiami$136K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Arthur LeeGainesville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.